Health News

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

Read more

Filed under: Pharmacy News
Tags: Drug, Pharmacy, Surgery

Related posts

• Use of bisphosphonates associated with risk of developing BON after dental surgery: Study (0)
  People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a study in the May issue of The Journal of the American Dental Association. Read more [tags] Pharmacy News [/tags]
  
  
• Study on non-surgical approach for treatment of liver hydatidosis (0)
  Concerning treatment, until recently the only definitive treatment for hydatid disease had been surgery. Different surgical techniques and procedures have been carried out and even in some cases, a liver transplant has been required. Advances in drug therapy has been influenced by the introduction of albendazole and accelerated by addition of praziquantel, but this requires [...]
  
  
• Strativa’s New Drug Application For Ondansetron Orally Dissolving Film Strip Accepted By FDA (0)
  Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ondansetron orally dissolving film strip (ODFS). Strativa is seeking approval of ondansetron ODFS for the prevention of nausea [...]
  
  
• Strativa Pharmaceuticals’ Zuplenz NDA: FDA issues complete response letter (0)
  Strativa Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the new drug application (NDA) for Zuplenz® (ondansetron) oral soluble film for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery. Read more [tags] Pharmacy News [/tags]
  
  
• Statins may improve longevity of hip replacement surgery (0)
  The use of statins - drugs commonly prescribed to help lower cholesterol levels - may play an important role in decreasing complications among patients undergoing total hip replacement (THR), according to a study published in the May 2010 issue of the Journal of Bone and Joint Surgery (JBJS). Read more [tags] Pharmacy News [/tags]